Current and emerging pharmacotherapy for the treatment of adult attention deficit hyperactivity disorder (ADHD).

Related Articles

Current and emerging pharmacotherapy for the treatment of adult attention deficit hyperactivity disorder (ADHD).

Expert Opin Pharmacother. 2019 May 21;:1-14

Authors: Perugi G, Pallucchini A, Rizzato S, Pinzone V, De Rossi P

Abstract
INTRODUCTION: ADHD is characterized by a developmentally inappropriate level of inattentiveness, impulsivity and/or hyperactivity. In adults, the disorder is frequently accompanied by Emotional Dysregulation (ED), associated to a variety of related psychiatric comorbidities, complicating its recognition and treatment management. Areas covered: This paper reviews randomized active comparator-controlled or placebo-controlled trials evaluating the use of pharmacotherapy in adults with ADHD and ED, other neurodevelopmental disorders, Bipolar Disorder (BD) and Anxiety Disorders (ADs). When controlled data are unavailable, the authors have included open-label and observational studies. Expert opinion: ED in adult patients with ADHD is a very common and impairing problem that can be treated with stimulants or atomoxetine. ADHD studies in adults with other neurodevelopment disorders are scarce; stimulants seem to be the most effective and safe drugs in treating ADHD symptoms, without worsening the core features of other neurodevelopmental disorders. In patients with ADHD and comorbid BD, the treatment of BD alone may result in residual symptoms of ADHD. Patients should be treated hierarchically: BD should be treated first, while ADHD should be treated combining ADHD medications and mood stabilizers after mood stabilization. The available evidence for treating patients with ADHD and comorbid ADs in adults supports the idea of an anti-anxiety/ADHD-specific treatment association.

PMID: 31112441 [PubMed – as supplied by publisher]

via https://www.ncbi.nlm.nih.gov/pubmed/31112441?dopt=Abstract